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Between November 1990 and November 1996, EORTC Children
Leukemia Group conducted a randomized trial in de novo acute
lymphoblastic leukemia and lymphoblastic non-Hodgkin’s
lymphoma patients using a Berlin–Frankfurt–Munster protocol
to evaluate the monthly addition of intravenous 6-mercapto-
purine (i.v. 6-MP) (1 g/m2) to conventional continuation therapy
comprising per oral MTX weekly and 6-MP daily. Only during
the first 18 months of the randomization period, 6-MP p.o. was
interrupted for 1 week after each i.v. 6-MP. A total of 877
patients was randomized to either no i.v. 6-MP (Arm A) or
additional i.v. 6-MP (Arm B). A total of 217 relapses (91 in Group
A vs 128 in Group B) and 13 deaths in CR (5 vs 8) were reported;
a total of 134 patients (55 vs 79) died. The median follow-up was
7.6 years. At 8 years, the disease-free survival rate was lower
(P¼ 0.005) in Arm B (69.1% (s.e.¼2.2%)) than in Arm A (77.9%
(s.e.¼ 2.0%)), and the hazard ratio was 1.45 (95% CI 1.12–1.89).
In conclusion, as delivered in this study, i.v. 6-MP was
detrimental to event-free survival.
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Introduction
Over the last 30 years, the results of the treatment of children
with acute lymphoblastic leukemia (ALL) and lymphoblastic
non-Hodgkin’s lymphoma (NHL) have greatly improved. After
the implementation of the total therapy concept,1 survival rates
reached approximately 50%. Further modifications of this total
therapy regimen have led to current survival rates of approxi-
mately 80%.2 Most of these modifications were introduced in
the initial phases of the treatment (induction, consolidation and
early or late intensification), whereas continuation therapy
remained almost unchanged. The latter combines daily per oral
6-mercaptopurine (6-MP) and weekly, usually per oral, metho-
trexate (MTX).3 These two drugs inhibit the de novo synthesis of
purines and have a synergistic effect. After oral administration,
presystemic metabolism of 6-MP causes an important first-pass
effect and results in reduced bioavailability and variable plasma
concentrations.4 The inactive prodrug 6-MP is further metabo-
lized intracellularly in cytotoxic and noncytotoxic products
(reviewed by Estlin et al).5
In a preliminary study by Camitta et al,6 it appeared that
intravenous 6-MP during postremission therapy of children with
ALL was of marked benefit when compared to historical
controls. Several reasons might explain a beneficial effect of
the intravenous route:6,7 by short-cutting the first-pass effect and
getting around the high variability of intestinal absorption,
parenteral administration should lead to higher tissue levels and
greater efficacy.8 As a result of higher plasma concentration,
intravenous (i.v.) administration of high doses of 6-MP enhances
its penetration into the cerebrospinal fluid and might reduce the
incidence of CNS relapses.9–11 Moreover, parenteral adminis-
tration guarantees better compliance.
For these reasons, the EORTC Children Leukemia Group
(CLG) decided to address the value of i.v. 6-MP given in
addition to conventional continuation therapy in a prospective
randomized phase III (58881) trial for patients with ALL or
lymphoblastic NHL. In the same trial, all or part of the patients
had been previously randomized for two other questions: at the
start of induction, the first randomization addressed the value of
Erwiniase as compared to Escherichia coli asparaginase.12 The
second question addressed the value of moderately high-dose
cytarabine when combined with high-dose methotrexate during
postinduction-consolidation therapy of increased-risk patients.13
The scope of this report is restricted to the evaluation of i.v.
6-MP during continuation therapy.
Patients and methods
Patients
The trial was started in July 1989 for patients under 18 years of
age with previously untreated ALL or lymphoblastic NHL.
Patients with mature B-cell ALL (Burkitt-like) or with non-
lymphoblastic NHL were excluded. The ALL patients were
stratified in a low, an increased and a very high-risk group as
previously defined.12–14 NHL patients were stratified according
to Murphy’s clinical stage:15 in the low-risk group if stage I or II
and in the increased-risk group if stage III or IV. NHL patients
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who failed induction therapy were switched to the very high-risk
group.12,13 Patients who relapsed were treated according to an
adapted Henze’s protocol.16 For registration of a child in the
study, an informed consent by his parents or his legal guardian
was required. The 58881 protocol has been approved by the
EORTC Protocol Review Committee and by the respective
ethical committees in each participating country.
Definitions and evaluations
When bone marrow involvement was observed, patients with
less than 25% of blasts in the bone marrow were considered as
having NHL. All cases were studied for specific lymphoblastic
cell characteristics, including morphology, immunophenotype
and cytogenetics. Morphologic classification of ALL was
according to the French–American–British classification.17
Classification of lymphomas was according to the working
formulation and the revised European–American Lymphoma
Classification.18 Frozen specimens or cell suspensions were
evaluated for B- and T-lineage-associated antigens with standard
techniques.19 Cytogenetic analysis of the lymphoblastic cells
was performed by R or G banding and chromosomes were
classified according to the International system for Human
Cytogenetic Nomenclature.20
For ALL, complete remission was defined as less than 5%
blasts in the bone marrow, recovery of normal hematopoiesis
and no evidence of disease at any other site. For NHL patients,
CR was defined by the disappearance of all clinical, imaging
and cytologic signs of lymphoma.
Central nervous system (CNS) leukemia was diagnosed when
neurologic abnormalities related to blastic infiltration of the CNS
were observed and/or when blasts were identified on cytocen-
trifuge examination of CSF in which white blood cell (WBC)
count was greater than 5 109 cells/l. Infectious, renal, hepatic
and neurologic toxicities were evaluated and graded according
to the World Health Organization grading system.21
Treatment
A Berlin–Frankfurt–Munster (BFM)-based protocol with slight
modifications was used.22 The therapy regimen was recently
described.12,13 During the course of the study, the randomiza-
tion period for the first question (Erwinia vs E. coli asparaginase)
did not coincide with that of the third question (addition or not
of i.v. 6-MP). The registration for asparaginase started 1 year
later than the registration for 6-MP: all patients registered during
the first year of the EORTC 58881 trial received E. coli
asparaginase from Bayer. In a second period, all patients were
randomized at diagnosis to receive either E. coli asparaginase
from MEDAC or Erwiniase. In a third period, after this
randomization was stopped because the inferiority of Erwiniase
had become evident, all patients received MEDAC E. coli
asparaginase as first-line treatment.12 Increased-risk patients
only were randomized to receive or not high-dose cytarabine
(HD Ara-C) during interval therapy.13
All patients were eligible for the third randomization if they
remained in first complete remission at the start of continuation
therapy: they were randomized to receive either conventional
treatment with only oral 6-MP and MTX, or to the same
treatment with the addition of 4-weekly i.v. 6-MP.
In the conventional arm, continuation therapy consisted of
oral 6-MP (50 mg/m2/day) and oral MTX (20 mg/m2/week). In the
experimental arm, i.v. 6-MP (1 g/m2 given over 8 h every 4
weeks) was added to the treatment. During the first 18 months of
the trial (November 1990–May 1992), daily oral 6-MP (but not
MTX) was interrupted for 1 week after each administration of i.v.
6-MP. After the first 18 months of the trial, the treatment
protocol was amended and henceforth called for uninterrupted
oral 6-MP treatment in all patients. In both arms, doses of per
oral drugs were adjusted in order to maintain the number of
leucocytes between 2 and 3 109/l.
Statistical analysis
Randomization for the 6-MP question was performed centrally
(EORTC Data Center, Brussels)23 before starting continuation
therapy. Patients were stratified according to center, risk-group
and previous randomization arms. The primary end point was
the disease-free survival (DFS) from the date of randomization to
the date of first relapse or to death in CR. The secondary end
points were the time from randomization to isolated CNS
relapse, with patients with other types of event (relapse, death in
CR) being censored at the time of event, and the duration of
survival (the time from randomization to death of any cause).
The actuarial curves were computed using the Kaplan–Meier
technique, and the standard errors (s.e.) of the estimates were
obtained via the Greenwood formula.24 The differences
between curves were tested for statistical significance using
the two-tailed log-rank test or the log-rank test stratified by a
categorical factor.24 To summarize the overall treatment
difference, the hazard ratio of having an event per time in arm
B vs in arm A was estimated via the Cox proportional hazards
model.25 For the overall comparison, the 95% confidence
interval (CI) of the hazard ratio was computed, and for two
subgroup analyses, the 97.5% CI was used, due to Bonferonni
correction for multiplicity. A total of 820 patients was intended
to be randomized in order to detect a significant difference in
terms of DFS at 5 years (70 vs 80%), corresponding to a hazard
ratio of 0.63 (alpha¼ 5%, beta¼ 20%). All analyses were
performed according to the intent-to-treat principle.
Results
Patients
Between November 1990 and November 1996, a total of 877
patients were randomized: 439 in the no i.v. 6-MP arm, 438 in
the i.v. 6-MP arm. The characteristics of both arms are listed in
Table 1. Among the 877 patients, 820 were diagnosed with ALL
and 57 with NHL: stage I (2 vs 2), stage II (4 vs 1), stage III (19 vs
15) and stage IV (4 vs 10). Patients’ characteristics were
generally well balanced in the two arms. In arm B, the
male:female ratio was slightly higher (1.39 vs 1.31) as compared
with arm A, and the incidence of high WBC (X100 109/l) was
also higher (10.9 vs 8.0%); the infants represented 1.4% in arm
B vs 1.8% in arm A, and ALL patients with VHR features
represented approximately 6% in both arms. The type of L-
asparaginase administered during the induction and intensifica-
tion phases as well as the type of interval therapy (with or
without high-dose cytarabine) were well balanced between the
two treatment groups.
Arm B was further divided into two groups: patients registered
before 1 January 1992 (randomized during the first 18 months of
the protocol), for whom 6-MP per oral was interrupted for 1
week after each administration of i.v. 6-MP, and those registered
later who had to receive uninterrupted per oral 6-MP. During
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the first period, 127 vs 124 patients were randomized in Arms A
and B, respectively, the majority of whom (79 vs 76) received
non-Medac asparaginase. During the second period, 312 vs 314
were randomized in the two arms, respectively, out of whom
594 (248 vs 246) received Medac asparaginase. Patients’
characteristics were well balanced between Arms A and B in
the first as well as the second periods.
Type of event by treatment group
At the time of analysis, the median follow-up was 7.6 years
(4–12 years). There were 230 events, including 217 relapses and
13 deaths without relapse. The crude rates of different sites of
relapse by treatment arm, in ALL and NHL patients are listed in
Table 2. There were more relapses in Arm B than in Arm A: 91
(20.7%) in Arm A vs 126 (28.8%) in Arm B. This difference was
mostly due to an increase of isolated bone marrow relapses (46
(10.5%) patients in Arm A vs 60 (13.7%) patients in Arm B) and
of combined CNS relapse (17 (3.9%) vs 27 (6.2%)). Isolated CNS
relapses (15 (3.4%) vs 17 (3.9%)) were evenly distributed. The 8-
year isolated CNS relapse rates were comparable as well: 3.6%
(Arm A) vs 4.3% (Arm B), hazard ratio¼ 1.16. A total of 12
patients died in CR: 5 (1.1%) in Arm A and 8 (1.8%) in Arm B.
DFS by treatment group
The DFS rate at 8 years was 69.1% (s.e.¼ 2.2%) for the patients
in Arm B and 77.9% (s.e.¼ 2.0%) for those in Arm A (Figure 1)
(logrank P¼ 0.005). The estimated hazard ratio was 1.45 (95%
CI 1.12–1.89). In ALL patients the estimated hazard ratio was
1.40 (97.5% CI 1.03–1.90) and in NHL patients is was 3.06
(97.5% CI 0.67–13.95). In the latter group, the adjustment
for Murphy stage let to a hazard ratio of 2.87 (97.5%
CI 0.62–13.38).
Multivariate analysis based on the Cox model indicated that
the difference remained highly significant (P¼ 0.006) between
the two groups (hazard ratio¼ 1.44, 95% CI 1.11–1.88) after
adjustment for the following factors: initial WBC count
(Po0.0001), type of asparaginase (P¼ 0.0001), age
(P¼ 0.0003) and sex (P¼ 0.01) (Table 3). Period of recruitment
was of prognostic importance only in univariate analysis
(P¼ 0.03). In multivariate analysis, it was not (P¼ 0.78) and
did not influence the magnitude of the treatment difference
(P¼ 0.64). Moreover, in multivariate setting, after adjustment for
the same prognostic factors, no significant interaction could be
determined between the type of asparaginase (Medac vs non-
Medac) and the randomized group (P¼ 0.22). In patients who
had received Medac E. coli asparaginase during induction and
intensification, the estimated hazard ratio of the comparison
Arm B vs Arm A was 1.29 (97.5% CI 0.87–1.91) in multivariate
setting, and in those who had received one of the other, less
potent asparaginases (E. coli asparaginase from Bayer or
Erwiniase) it was 1.73 (97.5% CI 1.09–2.75). Using a Cox
model, a prognostic score was defined based on the initial WBC,
the type of asparaginase, age and sex. Treatment remained
significant once adjusted for this score, but the interaction
between this score and the treatment arm was not significant
(P¼ 0.38), indicating that the treatment difference was quite
uniform among the risk groups defined by the above-mentioned
factors. Previous randomized treatment during interval therapy,
high-dose or no high-dose Ara-C, had absolutely no influence
on the treatment difference.
Duration of survival by treatment group
A total of 134 patients died: 55 in Arm A and 79 in Arm B. The
8-year survival rate was lower for the patients randomized in
Arm B than for those randomized in Arm A: 81.3% (s.e.¼ 2.0%)
vs 87.2% (s.e.¼ 1.7%) (Figure 2) (logrank P¼ 0.03). The
estimated hazard ratio was 1.46 (95% CI 1.04–2.07). In ALL
patients, the 8-year survival rates were 81.5% (s.e.¼ 2.0%) vs
86.5% (s.e.¼ 1.7%), and the hazard ratio was 1.36 (97.5%
CI 0.91–2.0.4). In NHL patients the 8-year survival rates were
77.7% (s.e.¼ 8.1%) vs 96.6% (s.e.¼ 1.8%), and the hazard ratio






ALL 410 (93.4) 410 (93.6)
NHL 29 (6.6) 28 (6.4)
Age at diagnosis (years)
o1 8 (1.8) 6 (1.4)
1–o10 362 (82.5) 357 (81.5)
X10 69 (15.7) 75 (17.1)
Gender
Male:female 249:190 255:183
Initial WBC (x 109/l)
o25 316 (72.0) 302 (68.9)
25–o50 50 (11.4) 48 (11.0)
50–o100 38 (8.7) 40 (9.1)
100–o250 20 (4.6) 32 (7.3)
X250 15 (3.4) 16 (3.7)
Immunophenotype
B-lineage 364 (82.9) 362 (82.6)
T-lineage 75 (17.1) 76 (17.4)
Chromosomes in ALL pts
Hyperdiploid 100 (24.4) 88 (21.5)
Diploid 110 (26.8) 102 (24.9)
Pseudodiploid 65 (15.9) 69 (16.8)
Hypodiploid 16 (3.9) 18 (4.4)
Other 41 (10.0) 44 (11.0)
Unknown 78 (19.0) 89 (21.7)
Initial Risk Factor in ALL patients16
Unknown 1 (0.2) 0 (0)
o0.8 154 (37.6) 153 (37.3)
0.8–o1.2 135 (32.9) 134 (32.7)
1.2–o1.7 105 (25.6) 101 (24.6)
X1.7 15 (3.7) 22 (5.4)
Initial CNS involvement in ALL pts
Unknown 0 (0.0) 3 (0.7)
Not involved 405 (98.8) 400 (97.6)
Involved/clinical signs 5 (1.2) 7 (1.7)
VHR features in ALL patients
Absence 380 (92.7) 384 (93.7)
Presence 30 (7.3) 26 (6.3)
Randomization to asparaginase
Not randomized (Bayer, E. coli) 32 (7.3) 34 (7.8)
Randomized to Medac, E. coli 118 (26.9) 116 (26.5)
Randomized to Erwiniase 111 (25.3) 110 (25.1)
Postrandomization (Medac, E. coli) 178 (40.5) 178 (40.6)
Year of registration and type of Asparaginase
o1992 and non-Medac asparaginase 79 (18.0) 76 (17.4)
o1992 and Medac asparaginase 48 (10.9) 48 (11.0)
X1992 and Non-Medac asparaginase 64 (14.6) 68 (15.5)
X1992 and Medac asparaginase 248 (56.5) 246 (56.2)
Randomization to HD Ara-C
Not randomized 57 (13.0) 53 (12.1)
Randomized to no HD Ara-C 96 (21.9) 95 (21.7)
Randomized to HD AraC 103 (23.5) 104 (23.7)
Low risk (not eligible) 183 (41.7) 186 (42.5)
Intravenous 6-MP in childhood ALL and NHL
J van der Werff ten Bosch et al
723
Leukemia
was 6.78 (97.5% CI 0.60–95.8). After adjustment for Murphy’s
stage, it was 5.61 (97.5% CI 1.88–5.61).
Multivariate analysis based on the Cox model led to the same
conclusions as for DFS (Table 3). Period of recruitment was not
of prognostic importance whether in univariate or multivariate
analysis (P¼ 0.88). No interaction between recruitment period
and treatment difference was observed (P¼ 0.82). The results in
Arm B were consistently worse than in Arm A independently
(P¼ 0.55) of the type of asparaginase received. After adjustment
for the prognostic score defined above, the difference remained
significant. The interaction between this score and treatment
arm was far from being significant (P¼ 0.79), indicating the
independence of the deleterious effect of i.v. 6-MP from this
score.
Toxicity and protocol compliance
Generally, toxic side effects were observed in both arms with
comparable frequency. Moderate and major infectious compli-
cations were evenly distributed between the two groups: 38.7%
in Arm A vs 36.4% in Arm B. The incidence of liver biologic
toxicities was higher in Arm B (22.0%) than in Arm A (16.6%).
The average daily dose/m2 of oral 6-MP actually given
throughout continuation therapy was lower (Po0.0001) in Arm
B as compared with Arm A: the median (mean) was 55.7
(57.0) mg/m2 in Arm A vs 47.9 (48.3) mg/m2 in Arm B. Patients
randomized in the first period of the trial received a median
Table 2 Type of first event in ALL and NHL patients, according to the randomized arm
ALL pts NHL pts ALL+NHL pts
Arm A Arm B Arm A Arm B Arm A Arm B
Continuous CR 317 (77.3) 284 (69.3) 26 (89.7) 20 (71.4) 343 (78.1) 304 (69.4)
Death in CR 5 (1.2) 7 (1.7) 0 (0.0) 1 (3.6) 5 (1.1) 8 (1.8)
Relapse 88 (21.5) 119 (29.0) 3 (10.3) 7 (25.0) 91 (20.7) 126 (28.8)
Bone marrow, isolated 46 (11.2) 57 (13.9) 0 (0.0) 3 (10.7) 46 (10.5) 60 (13.7)
CNS, isolated 15 (3.7) 17 (4.1) 0 (0.0) 0 (0.0) 15 (3.4) 17 (3.9)
CNS, combined 17 (4.1) 26 (6.3) 0 (0.0) 1 (3.6) 17 (3.9) 27 (6.2)
Gonads, isolated 2 (0.5) 5 (1.2) 0 (0.0) 0 (0.0) 2 (0.5) 5 (1.1)
Gonads+BM 6 (1.5) 6 (1.5) 0 (0.0) 0 (0.0) 6 (1.4) 6 (1.4)
Lymph nodes, isolated 0 (0.0) 0 (0.0) 1 (3.4) 1 (3.6) 1 (0.2) 1 (0.2)
Other 2 (0.5) 8 (1.9) 2 (6.8) 2 (7.1) 4 (0.9) 10 (2.3)
Total 410 (100) 410 (100) 29 (100) 28 (100) 439 (100) 438 (100)
Values are expressed as numbers and percent in parentheses.
Table 3 Results of the Cox proportional hazards model regarding the DFS and survival
End point Variable Hazard ratioa (95% CI) P-valueb
DFS
Randomized group: Arm B vs Arm A 1.44 (1.11, 1.88) 0.006
Initial WBCc 1.30 (1.17, 1.44) o0.0001
Sex (male vs female) 1.42 (1.09, 1.87) 0.01
Asparaginase (Non-Medac vs Medac) 1.66 (1.28, 2.16) 0.0001
Age (o1 year vs X1 year) 3.41 (1.74, 6.68) 0.0003
Survival
Randomized group: Arm B vs Arm A 1.42 (1.00, 2.00) 0.047
Initial WBCc 1.27 (1.12, 1.45) 0.0003
Sex (male vs female) 1.67 (1.16, 2.42) 0.006
Asparaginase (non-Medac vs Medac) 1.68 (1.19, 2.37) 0.003
Age (o1 year vs X1 year) 4.01 (1.86, 8.66) 0.0004
aA value41 indicates that the outcome is worse in the given category as compared with the baseline.
bP-value was determined by the Wald test.
cInitial white blood cell (WBC) count (109/l) categorized as: 1¼o25, 2¼25 to o50, 3¼50 to o100, 4¼100 to o250, 5¼X250.
Figure 1 DFS from randomization according to the randomized
arm. N¼ number of patients; O¼ observed number of events (relapses
or deaths in first CR). P-value was given by the logrank test.
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(mean) daily dose of oral 6-MP of 53.2 (53.6) vs 48.1 (45.6) mg/
m2 in Arms A and B, respectively. In the second period, this was
56.0 (57.9) vs 47.9 (49.2) mg/m2 in Arms A and B, respectively.
In Arm B, the median (mean) 4-weekly dose of i.v. 6-MP was
0.83 (0.73) g/m2; it was 0.90 (0.79) and 0.81 (0.70) g/m2 in the
first and second periods respectively.
Discussion
In contrast to what was expected from previous findings,6
randomization to i.v. 6-MP during continuation therapy has led
to significantly worse outcome. At 8 years, the DFS and survival
rates were approximately 9% (69.1 vs 77.9%) and 6% (81.3 vs
87.2%) lower, respectively, in Arm B.
Other studies have evaluated the efficacy of intermittent i.v.
6-MP as compared to protracted daily per oral 6-MP during
post-remission therapy either for all ALL patients26 or for some
risk-groups of patients.27–29 None of these studies showed any
benefit but no detrimental effect either from the use of i.v. 6-MP.
These studies differed from ours in at least two respects: they
evaluated i.v. 6-MP given instead of and not in combination
with per oral 6-MP. Moreover in two of these studies,27,29 i.v.
6-MP was started early during postremission therapy, concomi-
tantly with and before further intensive multiagent chemother-
apy or continuation therapy. Any possible detrimental effect of
i.v. 6-MP could thus have been erased by the efficacy of the
concomitant and subsequent treatment courses. By contrast, in
our study the addition of i.v. 6-MP jeopardized the efficiency of
the sole two drugs or at least of one of the two used in order to
eradicate any minimal residual disease still present.
As to why the addition of i.v. 6-MP was detrimental, two
possible reasons not necessarily mutually exclusive, may be
considered. The patients assigned to the i.v. 6-MP arm received
a moderately lower cumulative per oral dose. This difference
resulted, during the first 18 months of the trial, from the
mandatory interruption of per oral 6-MP during every fourth
week of the treatment and, throughout the whole of the study,
from more downward adjustments of the per oral 6-MP dosing.
However, for each period of the study, the deleterious effect of
i.v. 6-MP, adjusted for the type of asparaginase previously
administered and for other confounding factors remained
approximately the same: the increase of the event (relapse or
death in CR) rate per time unit in Arm B vs Arm A was 55% in
the first period and 39% in the second. Overall, the excess of the
event rate was 45% (hazard ratio¼ 1.45). It has already been
suggested that the total dose of 6-MP administered is positively
correlated with the DFS.30 The inferiority of Arm B could also
result from an inhibition by the i.v. 6-MP of the cytotoxic activity
of per oral 6-MP. This activity is mainly related to the
intracellular accumulation of 6-thioguanine nucleotides, which
are incorporated into DNA and lead to its damage.31 Alter-
natively, 6-MP is catabolized into inactive thiouric acid by
xanthine oxidase and methylmercaptopurine by thiopurine
methyltransferase. Unfortunately, we have no pharmacological
data that would have allowed us to verify the hypothesis that i.v.
6-MP could have modified the ratio of activating vs inactivating
enzymatic activities and thereby have led to a lower steady-state
intracellular concentration of thioguanine nucleotides.
Alternatively, Schmiegelow et al32 reported that if the doses of
6-MP given during continuation chemotherapy were tailored in
order to sustain high 6-TG levels, the incidence of relapse
increased after cessation of therapy in girls with ALL. These
authors speculated that above a hypothetical level of 6-TG,
residual leukemic cells escaped apoptosis by being maintained
in the G0 phase of the cell cycle and allowed to proliferate again
after chemotherapy had been stopped. In this regard, it is
noteworthy that in our study as well, the divergence of the two
DFS curves approximately started from completion of the
treatment (Figure 1).
In conclusion, whatever the mechanism involved, addition of
6-MP to continuation therapy was detrimental. Our results also
show that, notwithstanding the intensity of the initial induction,
consolidation and intensification courses of the BFM protocol,
small changes of the continuation therapy may lead to important
changes in outcome, which underlines the persisting impor-
tance of this treatment phase.
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